Pedioccus spp. based Microbiome Therapeutic Research Services
Welcome to the specialized research portal for Pediococcus spp. based Microbiome Therapeutic Research Services. As a premier Contract Research Organization (CRO) specializing in the preclinical development of Live Biotherapeutic Products (LBPs), Creative Biolabs provides end-to-end support for innovators harnessing the therapeutic potential of lactic acid bacteria.
Strategic Overview of Pediococcus Research
The genus Pediococcus represents a critical frontier in microbiome-based drug development. Traditionally valued in the food industry for their robust fermentation capabilities and production of potent bacteriocins (pediocins), these Gram-positive, homofermentative lactic acid bacteria (LAB) are now being repositioned as high-value Live Biotherapeutic Candidates.
Recent advancements have highlighted their unique ability to withstand the harsh conditions of the human gastrointestinal tract， specifically acid and bile stress， making them ideal vehicles for targeted therapeutic delivery. Our research services focus on the multi-dimensional characterization of these strains, exploring their roles in immunomodulation, intestinal barrier reinforcement, and the competitive exclusion of multi-drug resistant pathogens.
Discover Our Core Research Species
To explore specific therapeutic applications and genomic profiles, please select one of our primary research focuses below:
Known for its exceptional antioxidant and anti-inflammatory properties, this strain is a leading candidate for treating metabolic disorders and inflammatory bowel diseases through cytokine regulation and cholesterol-lowering pathways.
A robust probiotic powerhouse primarily researched for its ability to strengthen the gut-vascular barrier, produce high-titer pediocins against Listeria, and alleviate symptoms of gastrointestinal distress and hyperuricemia.
Comprehensive CRO Services for Preclinical Research
We provide an end-to-end service suite designed to accelerate your LBP pipeline. Our facilities are equipped to handle every stage of Pediococcus development, ensuring that your lead candidates meet stringent regulatory and scientific benchmarks.
Strain Characterization & Optimization
Genomic Profiling: Full WGS (Whole Genome Sequencing) to identify therapeutic genes, verify the absence of antibiotic resistance (AMR) genes, and ensure "Generally Recognized as Safe" (GRAS) compliance.
Metabolomic Analysis: Quantitative profiling of Short-Chain Fatty Acids (SCFAs), organic acids (Lactic, Acetic), and antimicrobial peptides.
Tolerance Assays: High-throughput screening for survival in simulated gastric juice and bile salt environments.
Cell Line Modeling: Using Caco-2, HT-29, and RAW 264.7 cell lines to evaluate adhesion capacity, anti-inflammatory effects, and intestinal barrier protection.
Co-culture Systems: Evaluating the interaction between Pediococcus strains and human intestinal organoids or complex fecal microbiota.
Pediococcus pentosaceus was isolated from soak pig's ear. They are coccus shaped microbes, Gram-positive, non-motile, non-spore forming, and are categorized as a "lactic acid bacteria". Pediococcus pentosaceus are able to grow in pH values between 4.5 and 8.0. Pediococcus are unique in that they form tetrads.
Pediococcus pentosaceus was isolated from naturally fermented milk. They are coccus shaped microbes, Gram-positive, non-motile, non-spore forming, and are categorized as a "lactic acid bacteria". Pediococcus pentosaceus are able to grow in pH values between 4.5 and 8.0. Pediococcus are unique in that they form tetrads.
Pediococcus pentosaceus was isolated from fermented milk. They are coccus shaped microbes, Gram-positive, non-motile, non-spore forming, and are categorized as a "lactic acid bacteria". Pediococcus pentosaceus are able to grow in pH values between 4.5 and 8.0. Pediococcus are unique in that they form tetrads.
Pediococcus pentosaceus are coccus shaped microbes, Gram-positive, non-motile, non-spore forming, and are categorized as a "lactic acid bacteria". Pediococcus pentosaceus are able to grow in pH values between 4.5 and 8.0. Pediococcus are unique in that they form tetrads.
Pediococcus pentosaceus are coccus shaped microbes, Gram-positive, non-motile, non-spore forming, and are categorized as a "lactic acid bacteria". Pediococcus pentosaceus are able to grow in pH values between 4.5 and 8.0. Pediococcus are unique in that they form tetrads.
This product contains high-quality, intact genomic DNA isolated from Pediococcus acidilactici Lindner Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Pediococcus pentosaceus Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Pediococcus ethanolidurans Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This mutant lacks a global regulator for the stress response. It is used in the food industry to study how lactic acid bacteria survive the harsh conditions of fermentation.
The therapeutic landscape for Pediococcus species has expanded far beyond general digestive health. Current preclinical and translational research programs are targeting several high-impact disease areas:
Pediococcus strains, particularly P. pentosaceus, have demonstrated significant efficacy in reducing the Disease Activity Index (DAI) in DSS-induced colitis models. The mechanism involves the downregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while simultaneously promoting the expression of tight junction proteins like ZO-1 and Occludin to repair "leaky gut" conditions.
Research indicates that specific Pediococcus isolates possess Bile Salt Hydrolase (BSH) activity. This enzymatic function facilitates the deconjugation of bile salts, leading to a reduction in serum cholesterol levels and improved lipid profiles. These strains are being developed as adjunctive therapies for obesity, non-alcoholic fatty acid liver disease (NAFLD), and Type 2 Diabetes.
3. Hyperuricemia and Gout
A novel application of Pediococcus acidilactici involves the modulation of uric acid metabolism. Preclinical studies show that these bacteria can decrease blood uric acid, creatinine, and urea nitrogen by inhibiting xanthine oxidase (XOD) activity and regulating the gut-kidney axis, offering a side-effect-free alternative to traditional urate-lowering drugs.
The production of Pediocins (Class IIa bacteriocins) gives Pediococcus a competitive edge against Gram-positive pathogens, including Listeria monocytogenes, Vancomycin-resistant Enterococci (VRE), and Clostridioides difficile. By forming pores in the cytoplasmic membranes of target pathogens, these strains serve as "living antibiotics" that do not disrupt the wider commensal microbiota.
Our Advantages
Deep Domain Expertise
Our scientific team consists of PhD-level microbiologists and immunologists with decades of experience in Lactic Acid Bacteria.
Integrated Platform
We offer a "One-Stop" solution, from initial strain isolation and genomic screening to advanced in vivo efficacy data.
Regulatory Alignment
Our study designs are aligned with guidelines for Live Biotherapeutic Products, facilitating smoother IND (Investigational New Drug) applications.
Data Integrity
State-of-the-art laboratory management systems ensure every data point is traceable and reproducible.
Partner with Us for the Future of LBPs
The emergence of Pediococcus as a significant player in the microbiome therapeutic space represents a shift toward more resilient and targeted biotherapies. By leveraging their natural antimicrobial properties and potent immunomodulatory effects, researchers are opening new doors for treating chronic inflammatory and metabolic diseases. At our CRO, we are dedicated to providing the high-resolution data and specialized expertise required to navigate this complex biological landscape.
The journey from a laboratory isolate to a life-changing therapeutic is fraught with technical challenges. Don't navigate the preclinical landscape alone. Partner with a CRO that understands the nuances of Pediococcus biology and the rigors of microbiome research. Together, we can unlock the full potential of these powerful microbes and bring the next generation of Live Biotherapeutics to the patients who need them most.
Why choose Pediococcus over more common Lactobacillus strains?
Pediococcus species often exhibit superior stability under various environmental stresses (heat, pH, oxygen) and produce unique bacteriocins like Pediocin AcH/PA-1, which are highly effective against specific pathogens that Lactobacillus may not target as efficiently.
Can your company assist with the scale-up of these strains?
Yes. While we focus on preclinical research, we provide optimized fermentation parameters and stability data that are crucial for transferring your process to a CDMO for clinical-grade manufacturing.
How do you ensure the safety of novel Pediococcus isolates?
We perform comprehensive safety audits, including phenotypic antibiotic susceptibility testing (following EFSA/ISO standards) and genomic screening for virulence factors and mobile genetic elements.
Are your disease models customizable?
Absolutely. We can adapt our animal models, such as adjusting the duration of a High-Fat Diet or using specific genetic backgrounds, to better reflect your target therapeutic indication.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
